natgillin/translations-raw huggingface dataset:
Table 1 Adverse drug reactions 
Preglednica 1 Neželeni učinki zdravila
Very common (may affect more than 1 in 10 people): • nausea (feeling sick) and vomiting 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov):
Treatment with lutetium (177Lu) oxodotreotide is not recommended for patients with severe heart failure defined as class III or class IV in the NYHA classification therefore, the benefit risk for these patients will always need to be weighed carefully. 
Lu) oksodotreotidom se ne priporoča za bolnike s hudim srčnim popuščanjem, opredeljenim kot razred III ali IV po razvrstitvi NYHA, zato je treba pri teh bolnikih vedno pozorno pretehtati koristi in tveganja.
In case of hyperkalaemia, patient's history of hyperkalaemia and concomitant medication should be checked. 
Če se pojavi hiperkaliemija, je treba preveriti hiperkaliemijo v bolnikovi anamnezi in zdravila, ki jih jemlje sočasno.
There were no non-clinical studies conducted with LysaKare. 
Predkliničnih študij z zdravilom LysaKare niso izvajali.
oxodotreotide and dose limiting if amino acids are not administered to reduce renal uptake and retention. 
Lu) oksodotreotida, in so omejujoči dejavnik za odmerek, če se z uporabo aminokislin ne zmanjša ledvični privzem in retencija.
How to take LysaKare 
Kako jemati zdravilo LysaKare
LysaKare infusion (see section 4.4). 
Lu) oksodotreotidom, zato glejte poglavje 4.4
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Polyethylene polyamine/aluminium foil 
Polietilen poliamin/aluminijeva folija
Hyperkalaemia must be corrected accordingly before starting the infusion (see section 4.3). 
Skladno s tem je treba pred začetkom infundiranja povrniti kalij na normalno raven (glejte poglavje 4.3).
Water for injections 
Pomožna snov: voda za injekcije
Do not use solutions which are cloudy or have deposits. 
Ne uporabljajte, če je raztopina motna ali ima oborino.
Treatment with lutetium (177Lu) oxodotreotide is not recommended for patients with renal function between 30 and 50 mL/min therefore, the benefit risk for these patients will always need to be weighed carefully, which should include consideration of an increased risk for transient hyperkalaemia in these patients (see section 4.4). 
Lu) oksodotreotidom ne priporoča, zato je treba pri teh bolnikih vedno pozorno oceniti razmerje med koristjo in tveganjem, kar mora vključevati upoštevanje povečanega tveganja za prehodno hiperkaliemijo pri teh bolnikih (glejte poglavje 4.4).
Do not use this medicine: - if you notice the solution is cloudy or has deposits. 
Ne uporabljajte tega zdravila: - če opazite, da je raztopina motna ali vsebuje oborino; - če je bil zunanji ovoj predhodno odprt ali poškodovan; - če je vreča za infundiranje poškodovana ali pušča.
The use of arginine and lysine has not been studied in patients with severe hepatic impairment. 
Uporabe arginina in lizina niso raziskovali pri bolnikih z jetrno okvaro.
Because feeling sick (nausea) and vomiting are commonly seen with amino acid infusions, you will be given medicines to prevent nausea and vomitting 30 minutes before the LysaKare infusion. 
Pri infundiranju aminokislin sta siljenje na bruhanje (navzea) in bruhanje pogosta, zato vam bodo 30 minut pred infundiranjem zdravila LysaKare dali zdravila, ki preprečujejo siljenje na bruhanje in bruhanje.
A dosimetry study including 6 patients showed that a 2.5% Lysine-Arginine amino acid solution reduced renal radiation exposure by about 47% as compared to no treatment, without having an effect on tumour uptake of lutetium (177Lu) oxodotreotide. 
Študija dozimetrije, pri kateri je sodelovali 6 bolnikov, je pokazala, da je 2,5-% raztopina aminoksilin lizina in arginina zmanjšala izpostavitev ledvic sevanju za približno 47 % v primerjavi s skupinami, ki niso prejemale zdravljenja, brez vpliva na privzem lutecijevega (
Nervous system disorders Dizziness 
Bolezni živčevja omotica
No pharmacokinetic data are available on the use of arginine and lysine at the same dose as LysaKare and for the same indication in paediatric patients. 
Farmakokinetičnih podatkov o uporabi arginina in lizina v odmerkih, ki ustrezajo odmerku v zdravilu LysaKare, in za isto indikacijo kot zdravilo LysaKare, pri pediatričnih bolnikih ni. 5.3 Predklinični podatki o varnosti
QUALITATIVE AND QUANTITATIVE COMPOSITION One 1,000 mL bag contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena 1.000-ml vreča vsebuje 25 g L-argininijevega klorida in 25 g L-lizinijevega klorida.
• Pre-existing clinically significant hyperkalaemia if not adequately corrected before starting the 
• Obstoječa klinično pomembna hiperkaliemija, če ni bila ustrezno popravljena pred začetkom infundiranja zdravila LysaKare (glejte poglavje 4.4).
LysaKare and lutetium (177Lu) oxodotreotide must be given through a separate infusion line. 
Lu) oksodotreotid je treba dajati po ločenih infuzijskih linijah.
As you will receive another treatment, Lutathera, with LysaKare, read the Lutathera leaflet carefully as well as this leaflet. 
Skupaj z zdravilom LysaKare boste prejeli tudi zdravilo Lutathera, zato pozorno preberite navodilo za uporabo zdravila Lutathera in to navodilo.
Treatment with lutetium (177Lu) oxodotreotide is not recommended for patients with renal function between 30 and 50 mL/min therefore, the benefit risk for these patients will always need to be weighed carefully, which should include consideration of an increased risk for transient hyperkalemia in these patients. 
Lu) oksodotreotidom ne priporoča, zato je treba pri teh bolnikih vedno pozorno oceniti razmerje med koristjo in tveganjem, kar mora vključevati upoštevanje povečanega tveganja za prehodno hiperkaliemijo pri teh bolnikih.
NAME OF THE MEDICINAL PRODUCT LysaKare 25 g/25 g solution for infusion 
LysaKare 25 g/25 g raztopina za infundiranje
Very common 
Zelo pogosti bruhanje
What LysaKare is 
Kaj je zdravilo LysaKare
PHARMACEUTICAL FORM AND CONTENTS Solution for infusion 
FARMACEVTSKA OBLIKA IN VSEBINA
NAME OF THE MEDICINAL PRODUCT LysaKare 25 g/25 g solution for infusion L-arginine hydrochloride/L-lysine hydrochloride 
LysaKare 25 g/25 g raztopina za infundiranje L-argininijev klorid/ L-lizinijev klorid
What LysaKare is used for 
Za kaj uporabljamo zdravilo LysaKare
Talk to your doctor before taking LysaKare if your kidneys, heart or liver are severely impaired or if you have a history of high blood levels of potassium (hyperkalaemia). 
Če imate hudo okvaro ledvic, srca ali jeter, ali če ste v preteklosti imeli visoke vrednosti kalija v krvi (hiperkaliemijo), se pred uporabo zdravila LysaKare posvetujte z zdravnikom.
LysaKare is given as an infusion (drip) into a vein. 
Zdravilo LysaKare se daje z infundiranjem v veno.
LysaKare is indicated for administration with PRRT with lutetium (177Lu) oxodotreotide therefore, it should only be administered by a health care provider experienced in the use of PRRT. 
Lu) oksodotreotidom, torej ga lahko dajejo samo zdravstveni delavci z izkušnjami pri uporabi PRRT.
An increase of serum potassium levels may occur in patients receiving arginine and lysine. 
Pri bolnikih ki prejemajo arginin in lizin se lahko zvišajo ravni kalija v serumu.
Patiens with hepatic impairment 
Bolniki z jetrno okvaro
In case of severe symptomatic hyperkalaemia, discontinuation of LysaKare infusion should be considered, taking into consideration the risk-benefit of renal protection versus acute hyperkalaemia. 
Pri tem je treba upoštevati razmerje med koristjo zaščite ledvic in tveganjem za akutno hiperkaliemijo.
Each infusion bag contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride. 
Ena vreča za infundiranje vsebuje 25 g L-argininijevega klorida in 25 g L-lizinijevega klorida.
How to store LysaKare 
Shranjevanje zdravila LysaKare
Clear, colourless solution, free from visible particles pH: 5.1 - 6.1 
Bistra, brezbarvna raztopina brez vidnih delcev.
OTHER SPECIAL WARNING(S), IF NECESSARY Do not reconnect partially used bags. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
LysaKare should be administered as a 4-hour infusion (250 mL/hour) starting 30 minutes prior to administration of lutetium (177Lu) oxodotreotide to achieve optimal renal protection. 
Zdravilo LysaKare je treba dajati s 4-urnim infundiranjem (250 ml/h), ki naj se začne 30 minut pred dajanjem lutecijevega (
The overwrap is a moisture barrier. 
Zunanji ovoj je zaščita pred vlago.
LysaKare is used in adult patients to protect kidneys from unnecessary radiation during treatment with Lutathera (lutetium (177Lu) oxodotreotide), a radioactive medicine used to treat certain tumours. 
Lu) oksodotreotidom), radioaktivnim zdravilom, ki se uporablja za zdravljenje določenih tumorjev.
Adverse drug reaction 
Neželen učinek zdravila
Arginine and lysine undergo glomerular filtration and, via competition, interfere with renal resorption of lutetium (177Lu) oxodotreotide, reducing the radiation dose delivered to the kidney. 
oksodotreotida v ledvicah ter tako zmanjšata dozo sevanja, ki se dovaja v ledvice.
LysaKare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults. 
Zdravilo LysaKare je indicirano za zmanjševanje izpostavitve ledvic sevanju med radionuklidno terapijo peptidnega receptorja (Peptide-Receptor Radionuclide Therapy - PRRT) z lutecijevim (
Renal impairment 
Bolezni prebavil navzea
4.6 Fertility, pregnancy and lactation 
• siljenje na bruhanje in bruhanje
The risk caused by radioactivity is thought to be very low. 
Tveganje zaradi radioaktivnosti je predvidoma zelo majhno.
This summary was last updated in 04-2011. 
Povzetek je bil nazadnje posodobljen 07-2010.
• dementia (loss of intellectual function). 
• demence (izguba intelektualnih sposobnosti).
It must not be used in women who are pregnant. 
Zdravilo se ne sme uporabljati pri nosečnicah.
The medicine is used to help in the diagnosis of the following conditions in adults (aged 18 years or over): 
Zdravilo se uporablja za pomoč pri diagnosticiranju naslednjih bolezenskih stanj pri odraslih (starejših od 18 let):
In the larger of the two studies, the sensitivity of DaTSCAN was 97%. 
V večji od obeh študij je bila občutljivost zdravila DaTSCAN 97-odstotna.
The European Commission granted a marketing authorisation valid throughout the European Union for DaTSCAN to GE Healthcare Limited on 27 July 2000. 
Evropska komisija je dovoljenje za promet z zdravilom DaTSCAN, veljavno po vsej Evropski uniji, odobrila družbi GE Healthcare Limited dne 27. julija 2000.
In movement disorders, DaTSCAN has been studied in 254 adults in two main studies. 
Pri motnjah gibanja so zdravilo DaTSCAN proučevali pri 254 odraslih v dveh glavnih študijah.
In the studies, images obtained in 45 healthy volunteers were compared with those obtained in 180 patients with Parkinson's disease or related diseases, and in 29 patients with essential tremor. 
V študijah so slike, dobljene pri 45 zdravih prostovoljcih, primerjali s tistimi, dobljenimi pri 180 bolnikih s Parkinsonovo boleznijo ali povezanimi obolenji, ter pri 29 bolnikih z esencialnim tremorjem.
In all of the studies, the main measure of effectiveness was the accuracy of the diagnosis based on the images from the scan compared with the diagnosis made by a specialist doctor. 
V vseh študijah je bilo glavno merilo učinkovitosti točnost diagnoze, ugotovljene na podlagi slik, v primerjavi z diagnozo, ki jo je ugotovil zdravnik specialist.
Other information about DaTSCAN: 
Druge informacije o zdravilu DaTSCAN:
For more information about treatment with DaTSCAN, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom DaTSCAN preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
This document is a summary of the European public assessment report (EPAR) for DaTSCAN. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo DaTSCAN.
This means that the disease identified by the doctor reading the images obtained using DaTSCAN matched the existing diagnosis of the patients in 97% of cases. 
To pomeni, da je bolezen, kot jo je opredelil zdravnik, ki je tolmačil slike, pridobljene ob uporabi zdravila DaTSCAN, v 97 % ustrezala že obstoječi diagnozi bolnikov.
DaTSCAN is only handled and given by people who have experience in the safe handling of radioactive materials. 
Z zdravilom DaTSCAN lahko rokujejo in ga dajejo le osebe, ki imajo izkušnje z varnim ravnanjem z radioaktivnimi snovmi.
If this happens, the amount of DaTSCAN attaching to these nerve cells is greatly reduced, which can be seen on the scan. 
Če se to zgodi, je količina zdravila DaTSCAN, ki se veže na te živčne celice močno zmanjšana, kar se vidi na sliki.
In movement disorders, DaTSCAN was effective at detecting changes in the brain due to Parkinson's disease or related diseases. 
Pri motnjah gibanja je bilo zdravilo DaTSCAN učinkovito pri zaznavanju sprememb v možganih, nastalih zaradi Parkinsonove bolezni ali povezanih bolezni.
A scan is taken three to six hours after the injection. 
Tri do šest ur po injiciranju se opravi slikanje.
What benefit has DaTSCAN shown during the studies? 
Kakšne koristi je zdravilo DaTSCAN izkazalo med študijami?
In dementia, the sensitivity of DaTSCAN in distinguishing dementia caused by Lewy bodies from other types of dementia ranged from 75 to 80%. 
Pri demenci je bila občutljivost zdravila DaTSCAN pri razlikovanju demence, ki jo povzročajo Lewyjeva telesca, od drugih tipov demence 75- do 80-odstotna.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DaTSCAN. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo DaTSCAN, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
In dementia, DaTSCAN has been studied in one main study involving 288 adults who had been diagnosed with dementia with Lewy bodies or Alzheimer's disease, or another form of dementia. 
Pri demenci so zdravilo DaTSCAN proučevali v eni glavni študiji pri 288 odraslih bolnikih z diagnosticirano demenco z Lewyjevimi telesci ali Alzheimerjevo boleznijo, ali katero drugo obliko demence.
In patients with Parkinson's disease and related diseases, and in patients with dementia with Lewy bodies, there is typically a loss of nerve cells in the striatum containing dopamine. 
Pri bolnikih s Parkinsonovo boleznijo in povezanimi obolenji ter bolnikih z demenco z Lewyjevimi telesci gre navadno za izgubo živčnih celic v striatumu, ki vsebujejo dopamin.
The CHMP decided that DaTSCAN's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila DaTSCAN večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
• movement disorders such as those seen in Parkinson's disease and other related diseases, where a loss of nerve cells leads to tremor (shaking), gait disturbance (problems with the way the patient walks) and stiffness of the muscles. 
• težav pri gibanju, kakršne se opazijo pri Parkinsonovi bolezni in drugih sorodnih boleznih, kjer izguba živčnih celic privede do tremorja (tresenja), motenj pri hoji in otrplosti mišic.
DaTSCAN is given by slow injection lasting no less than 15 to 20 seconds into an arm vein. 
Zdravilo DaTSCAN se daje v veno na roki s počasnim injiciranjem, ki traja najmanj 15 do 20 sekund.
What is the risk associated with DaTSCAN? 
Kakšna tveganja so povezana z zdravilom DaTSCAN?
This can be seen using a special imaging technique called single-photon-emission computed tomography (SPECT), which detects the radioactive iodine-123. 
To lahko opazujemo s posebno tehniko slikanja, imenovano enofotonska izsevna tomografija ali SPECT (single photon emission computed tomography), ki zazna radioaktivni jod-123.
DaTSCAN should only be used in patients who have been referred by a doctor with experience in the management of movement disorders or dementia. 
Zdravilo DaTSCAN se lahko uporablja le pri bolnikih, ki jih je napotil zdravnik z izkušnjami v obravnavanju motenj gibanja ali demence.
DaTSCAN is used to help distinguish between a type of dementia known as ‘dementia with Lewy bodies' and Alzheimer's disease. 
Zdravilo DaTSCAN se uporablja za razločevanje med vrsto demence, ki je znana kot „demenca z Lewyjevimi telesci“, in Alzheimerjevo boleznijo.
It is used to detect the loss of nerve cells in an area of the brain called the striatum, specifically the cells that release dopamine, a chemical messenger. 
Uporablja se za ugotavljanje izgube živčnih celic v določenem predelu možganov, ki se imenuje striatum, zlasti celic, ki sproščajo kemijski prenašalec dopamin.
DaTSCAN is for diagnostic use only. 
Zdravilo DaTSCAN je samo za diagnostične namene.
Ioflupane attaches specifically to structures on the surface of nerve cell endings in the striatum that are responsible for the transport of dopamine. 
Ioflupan se veže na strukture na površini končičev živčnih celic v striatumu, ki so odgovorne za prenašanje dopamina.
When receiving DaTSCAN, patients must also take another medicine, such as iodine tablets, to prevent their thyroid gland from taking up the iodine contained in DaTSCAN. 
Bolniki morajo med prejemanjem zdravila DaTSCAN jemati tudi drugo zdravilo (kot so tablete joda), ki njihovi ščitnici preprečuje absorpcijo joda iz zdravila DaTSCAN.
When DaTSCAN is injected, ioflupane (123I) is distributed through the body in the blood and accumulates in the striatum, where it attaches to the structures that transport dopamine. 
Ko se zdravilo DaTSCAN injicira, se ioflupan (123I) prek krvi porazdeli po telesu in se zbere v striatumu, kjer se veže na strukture, ki prenašajo dopamin.
DaTSCAN should not be used in people who may be hypersensitive (allergic) to ioflupane or any of the other ingredients. 
Zdravila DaTSCAN ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) ali katero koli drugo sestavino zdravila.
Why has DaTSCAN been approved? 
Zakaj je bilo zdravilo DaTSCAN odobreno?
This enables diseases related to Parkinson's disease to be distinguished from essential tremor, and for Lewy body dementia to be distinguished from Alzheimer's disease. 
To omogoča ločiti obolenja, povezana s Parkinsonovo boleznijo, od esencialnega tremorja, ter demenco z Lewyjevimi telesci od Alzheimerjeve bolezni.
DaTSCAN is a solution for injection that contains the active substance ioflupane (123I). 
Zdravilo DaTSCAN je raztopina za injiciranje, ki vsebuje zdravilno učinkovino ioflupan (123I).
It contains a substance called ioflupane, which is labelled with 123I (iodine-123), a radioactive form of the chemical element iodine. 
Vsebuje spojino imenovano ioflupan, ki je radioaktivno označena z 123I (jod-123), radioaktivno obliko kemičnega elementa joda.
For the full list of all side effects reported with DaTSCAN, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila DaTSCAN, glejte navodilo za uporabo.
This is taken one to four hours before DaTSCAN. 
To zdravilo je treba vzeti eno do štiri ure pred in 12 do 24 ur po prejemu odmerka zdravila DaTSCAN.
The most common side effect with DaTSCAN (seen in between 1 and 10 patients in 100) is headache. 
Najpogostejši neželeni učinki zdravila DaTSCAN (opaženi pri 1 do 10 bolnikih izmed 100) so povečan tek, glavobol, mravljinčenje in vrtoglavica.
Because tremor can also occur in ‘essential tremor' (tremor whose cause is unknown), DaTSCAN is used to help distinguish between essential tremor and diseases related to Parkinson's disease; 
Ker se tremor lahko pojavi tudi pri „esencialnem tremorju“ (tremor, katerega vzrok ni znan), se zdravilo
The active substance in DaTSCAN, ioflupane (123I), is a radiopharmaceutical. 
Zdravilna učinkovina zdravila DaTSCAN, ioflupan (123I), spada med radiofarmacevtske izdelke.
Resuscitation equipment should be available before DaTSCAN is given, in case the patient has an allergic reaction. 
Ker lahko pri bolniku pride do alergijske reakcije, mora biti pred začetkom injiciranja zdravila DaTSCAN na voljo oprema za oživljanje.
How has DaTSCAN been studied? 
Kako je bilo zdravilo DaTSCAN raziskano?
What is DaTSCAN used for? 
Za kaj se zdravilo DaTSCAN uporablja?
How is DaTSCAN used? 
Kako se zdravilo DaTSCAN uporablja?
What is DaTSCAN? 
Kaj je zdravilo DaTSCAN?
How does DaTSCAN work? 
Kako zdravilo DaTSCAN deluje?
The full EPAR for DaTSCAN can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo DaTSCAN je na voljo tukaj.
Packaging Content Package sizeWithdrawal period 
Ovojnina Vsebina Velikost pakiranja
EU Number 
EU številka Izmišljeno ime
(Invented) Name 
Izmišljenoime Jakost
Pack size 
Pot uporabe Ovojnina
If pain persists for more than 12 hours, the doctor should be consulted again. 
Če bolečina ne izgine po več kot 12 urah, se je treba ponovno posvetovati z zdravnikom.
The vaccine was first studied in a number of laboratory studies in pigs. 
Cepivo so najprej proučevali v več laboratorijskih študijah pri prašičih.
In the future, if the animals are exposed to the virus the immune system will be able to respond more quickly. 
Ob ponovni izpostavitvi živali virusu v prihodnosti se bo imunski sistem tako hitreje odzval.
The vaccine does not contain any live PCV2 so that it cannot cause disease. 
Cepivo ne vsebuje živega virusa PCV2, zato ta ne more povzročati bolezni.
The full EPAR for Porcilis PCV ID can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila Porcilis PCV ID je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Porcilis PCV ID's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Porcilis PCV ID večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Porcine circovirus vaccine (inactivated) 
cepivo proti prašičjemu cirkovirusu (inaktivirano)
The vaccine contains small amounts of a protein from PCV2. 
Cepivo vsebuje majhne količine beljakovine iz virusa PCV2.
The laboratory studies showed that the vaccine had its full effect against PCV2 by two weeks and that protection lasted 23 weeks after vaccination. 
Laboratorijske študije so pokazale, da je cepivo svoj polni učinek proti OCV2 doseglo v dveh tednih in da je zaščita trajala 23 tednov po cepljenju.
This is a summary of the European public assessment report (EPAR) for Porcilis PCV ID. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Porcilis PCV ID.
The vaccine is given using a suitable needle-free device for injection into the skin. 
Cepivo se daje z ustrezno napravo brez igle za injiciranje v kožo.
The European Commission granted a marketing authorisation valid throughout the EU for Porcilis PCV ID on 28 August 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Porcilis PCV ID, veljavno po vsej Evropski uniji, izdala 28. avgusta 2015.
When Porcilis PCV ID is given to pigs, the animals' immune system recognises the virus protein as ‘foreign' and reacts by building up an active immune response. 
Ko prašiči prejmejo cepivo Porcilis PCV ID, imunski sistem živali prepozna beljakovino iz virusa kot „tujek“ ter se nanj odzove tako, da sproži aktivni imunski odziv.